Journal article
Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy
A Srikanthan, B Tran, M Beausoleil, MAS Jewett, RJ Hamilton, JFG Sturgeon, M O'Malley, L Anson-Cartwright, PWM Chung, PR Warde, E Winquist, MJ Moore, E Amir, PL Bedard
Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Abstract
Purpose: Cisplatin-based chemotherapy, a mainstay of treatment for disseminated germ cell tumors (GCTs), is associated with venous thromboembolism (VTE). Many patients with disseminated GCTs have large retroperitoneal lymph node (RPLN) metastases that may cause venous stasis and increase the risk of VTE development. We hypothesized that there was an association between large RPLN and chemotherapy-associated VTE risk. Patients and Methods: The training cohort was composed of patients with disseminated GCT receiving first-line chemotherapy at Princess Margaret Cancer Centre between January 2000 and December 2010. Large RPLN was defined as more than 5 cm in maximal axial diameter. The predictiv..
View full abstractGrants
Funding Acknowledgements
Sanofi (Inst) GlaxoSmithKline (Inst), Medivation (Inst), Sanofi (Inst), ImClone Systems (Inst), Oncolytics Biotech (Inst), Eisai (Inst), Hoffman-La Roche (Inst), Oncothyreon (Inst), Exelixis (Inst), Astellas Pharma (Inst), Boehringer Ingelheim (Inst), Oncogenex (Inst) Sanofi (Inst), GlaxoSmithKline (Inst)